Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Do not try to persuade, says Dr Winnett, but provide safety data and rebound rate research results to help patients make informed decisions. Use the conversation as an opportunity to explain that obesity is a chronic condition, and stopping medication marks a transition, not the end of treatment
Just like high blood pressure and high cholesterol, where we do not stop medications once a person reaches the target, it is not recommended to stop GLP-1 medications once a person has reached their goal weight," says Cynthia Odogwu, M.D
For women, Monica recommends the Tesamorelin/Ipamorelin blend at 150/50 mcg, in the PM while fasted, 5x per week, 8 weeks on then 6-8 weeks off
doi: 10.3389/fphar.2025.1735760 Received 30 October 2025 Revised 14 December 2025 Accepted 19 December 2025 Published 27 February 2026 Volume 16 - 2025 Edited by Vigyasa Singh, University of Arizona, United States Reviewed by Mayasah Al-Nema, University of British Columbia, Canada Rituraj Purohit, Institute of Himalayan Bioresource Technology (CSIR), India Chiara Brullo, University of Genoa, Italy Updates Copyright 2026 Rautela, Gaurav, Nissapatorn, Tan, Girol, Pereira and Lee
CrossRef Non-alcoholic fatty liver disease and Helicobacter pylori infection: problems and solutions
